Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

Non─ small cell lung cancer (NSCLC) presents different druggable genetic abnormalities,
including ROS1 and ALK rearrangements, which share relevant clinical features and …

Venous thromboembolism (VTE) associated with cancer (CAT) is a well-described
complication of cancer and a leading cause of death in patients with cancer. The purpose of …

Currently, lung cancer is treated by the highest number of therapeutic options and the
benefits are based on multiple large‐scale sequencing studies, translational research and …

Introduction Increased thromboembolism (TE) has been reported in ALK+ and ROS1+ non-
small cell lung cancer (NSCLC). Materials and Methods Odds ratios (OR) and hazard ratios …

Introduction Thromboembolism (TE) is common in patients with non‐small cell lung cancer
(NSCLC) and is associated with worse outcomes. Recent advances in the understanding of …

Venous thromboembolism (VTE) is a common complication in patients with cancer and
portends a poor prognosis. Our understanding of the underlying pathophysiology of VTE in …

Introduction Clinical venous thromboembolism (VTE) risk prediction scores, such as the
Khorana Risk Score, perform poorly in NSCLC, possibly because the tumor molecular …

Background Patients with cancer are at increased risk for venous thromboembolism (VTE),
and 8% to 15% of patients with advanced non–small-cell lung cancer (NSCLC) experience …